ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2793

Molecular Mimicry and Autoimmunity: Anti-P. Gingivalis antibody Response in ACPA-Positive Rheumatoid Arthritis

Natalia Sherina1, Natalie Sippl1, Lena Israelsson1, Erwan Le Maitre2, Nastya Kharlamova1, Monika Hansson3, Kaja Eriksson4, Tulay Yucel-Lindberg4, Khaled Amara1 and Karin Lundberg1, 1Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, 2Rheumatology Unit, Department of Medicine, Solna,, Karolinska Institutet, Stockholm, Sweden, 3Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 4Division of Periodontology, Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: ACPA, autoantibodies, bacterial infections and rheumatoid arthritis (RA), Periodontitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: 5T085 ACR Abstract: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (2791–2796)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: The presence of anti-citrullinated protein antibodies (ACPA) is a hallmark of rheumatoid arthritis (RA). ACPAs specifically recognize citrullinated epitopes, a result of a post-translational modification catalyzed by peptidyl arginine deiminases (PAD). Based on the unique feature of the periodontal bacteria Porphyromonas gingivalis (P.g) to express P.PAD it has been suggested that ACPA-positive RA may be precipitated in the gum mucosa. To address this hypothesis, we have investigated the antibody response against a citrullinated peptide derived from P.PAD (CPP3) in patients with RA, patients with chronic periodontitis (PD), and in controls. In addition, we have cloned B cells from gingival tissue of a patient suffering from both PD and RA and generated monoclonal antibodies (mAbs) with an aim to demonstrate that citrulline-specific B cells, previously detected only in RA joints and circulation, may also reside in gingival tissue.

Methods: Gingival tissue-derived single CD19+B cells from an ACPA-positive RA patient with PD were sorted by flow cytometry. Immunoglobulin variable region genes were sequenced and expressed to generate recombinant mAbs. CPP3-reactivity was analysed by ELISA in serum samples from 66 PD patients, 63 periodontally healthy controls (non-PD), 200 RA patients, and 120 systemically healthy controls (non-RA), as well as in 55 mAbs. Differences in antibody levels were examined using Mann-Whitney U test for independent groups.

Results: Anti-CPP3 antibody levels were low in non-PD controls, while 65% of PD patients showed elevated levels (p<0.0001). Significantly increased antibody levels were also detected in 50% of ACPA-positive RA, 20% of ACPA-negative RA, and in 37% of non-RA controls (p<0.0001). Notably, this antibody response was citrulline-specific, as the antibody response against the arginine-containing control peptide RPP3 was significantly lower in all subsets (p<0.0001). Among 55 mAbs from gingival tissue, 14 (25%) unique clones were CPP3-reactive, of which 4 showed cross-reactivity with RPP3. Interestingly, 4 out of 14 (29%) CPP3-reactive clones also bound citrullinated peptides derived from human a-enolase, filaggrin and histone4, demonstrating cross-reactivity between a bacterial epitope and human epitopes on a monoclonal level.

Conclusion: This study shows that a substantial proportion of systemically healthy individuals possess ACPAs directed against P.g, and these ACPAs also bind epitopes on human proteins. Based on our data, we propose that the ACPA response may be triggered by P.g, via an antibody response against CPP3, which cross-reacts with human citrullinated proteins by mechanisms of molecular mimicry.


Disclosure: N. Sherina, None; N. Sippl, None; L. Israelsson, None; E. Le Maitre, None; N. Kharlamova, None; M. Hansson, None; K. Eriksson, None; T. Yucel-Lindberg, None; K. Amara, None; K. Lundberg, None.

To cite this abstract in AMA style:

Sherina N, Sippl N, Israelsson L, Le Maitre E, Kharlamova N, Hansson M, Eriksson K, Yucel-Lindberg T, Amara K, Lundberg K. Molecular Mimicry and Autoimmunity: Anti-P. Gingivalis antibody Response in ACPA-Positive Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/molecular-mimicry-and-autoimmunity-anti-p-gingivalis-antibody-response-in-acpa-positive-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/molecular-mimicry-and-autoimmunity-anti-p-gingivalis-antibody-response-in-acpa-positive-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology